



High-Impact Clinical Trials

Hall A

Moderators: Donald Fraser, MBChB, PhD; Tamara Isakova, MD

Note: Full abstracts will be posted online on November 3, 2023.

-
- 10:30 a.m. **FR-OR108 Sparsentan (SPAR) vs. Irbesartan (IRB) in Patients with Focal Segmental Glomerulosclerosis (FSGS): Results from the Phase 3 DUPLEX Trial** – [Michelle N. Rheault](#), Howard Trachtman, Ulysses Diva, Radko Komers, On behalf of the DUPRO steering committee and DUPLEX investigators
- 10:45 a.m. **FR-OR109 Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan (SPAR) vs. Irbesartan (IRB) in Patients with Immunoglobulin A Nephropathy (IgAN)** – [Brad H. Rovin](#), Jonathan Barratt, Ulysses Diva, Radko Komers, Vlado Perkovic, On behalf of the DUPRO steering committee and PROTECT investigators
- 11:00 a.m. **FR-OR110 AYAME Study: Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Bardoxolone Methyl in Diabetic Kidney Disease (DKD) Patients** – [Tadao Akizawa](#), Kengo Yamawaki, Tomohiro Ichikawa, Kazuya Mukai, Masaomi Nangaku
- 11:15 a.m. **FR-OR111 Aldosterone Synthase Inhibition with or Without Background Sodium Glucose Cotransporter 2 Inhibition in CKD: A Phase II Clinical Trial** – [Katherine R. Tuttle](#), Sibylle J. Hauske, Lisa Cronin, Zhichao Sun, Dick de Zeeuw, Hiddo J. Heerspink, Peter Rossing
- 11:30 a.m. **FR-OR112 ZENITH-CKD: A Phase 2B Study of Zibotentan in Combination with Dapagliflozin and Dapagliflozin Alone in Patients with CKD** – [Hiddo J. Heerspink](#), Arihiro Kiyosue, David C. Wheeler, Min Lin, Emma Wijkmark, Glenn F. Carlson, Anne-Kristina Mercier, Magnus Åstrand, Sebastian Ueckert, Peter J. Greasley, Philip D. Ambery
- 11:45 a.m. **FR-OR113 Aldosterone Antagonist Chronic HEModialysis Interventional Survival Trial (ALCHEMIST): Primary Results** – [Patrick Rossignol](#), Faiez Zannad, Ziad Massy, Michel Azizi, Julien Coadic, Angélique Tenailleau, Dominique Mottier, Francis Guillemin, Fatima Chorfa, Delphine Maucourt-Boulch, Luc Frimat
- 12:00 p.m. **FR-OR114 Effect of a Multi-Component Intervention to Improve Patient Access to Kidney Transplantation and Living Kidney Donation** – [Amit X. Garg](#), Seychelle Yohanna, Kyla L. Naylor, Susan Q. McKenzie, Istvan Musci, Stephanie N. Dixon, Bin Luo, Jessica M. Sontrop, Peter G. Blake, Enhance Access to Kidney Transplant and Living Kidney Donation (EnAKT LKD) Investigators
- 12:15 p.m. **FR-OR115 MDR-101-MLK Update: Operational Immune Tolerance Achieved in Living Related HLA-Matched Kidney Transplant Recipients** – [Dixon Kaufman](#), Mark D. Stegall, Sanjeev Akkina, James B. Piper, William S. Asch, Stephan Busque, Ahmed O. Gaber, Martin L. Mai, Michael E. de Vera, Suzon Collette, Anup M. Patel, Ashesh P. Shah, Erik Stites, Lenuta Micsa, Daniel C. Brennan
- 12:30 p.m. Adjourn



Late-Breaking Clinical Trials Posters

Exhibit Hall

Note: Full abstracts will be posted online on November 2, 2023.

- TH-PO1113 Graft Function and Other Outcomes in Kidney Transplant Recipients Converting from Immediate-Release to Prolonged-Release Tacrolimus** – [Bernhard K. Krämer](#), Nassim Kamar, László Kóbori, Mathilde Lemoine, Balazs Nemes, Su Hyung Lee, Hai An P. Ha, Yoshihiko Watarai, Jaeseok Yang, Seungyeup Han, Dirk R. Kuypers, Martin Blogg, Alexander Harkavyi, Carola Repetur, Ludmila Scrine, Mohamed Soliman
- TH-PO1114 Clinical Impact of the Predigraft/iBox System as a Clinical Decision Support for Kidney Transplant Patients' Management: Mid-Term Results of a Prospective Randomized Controlled Trial (RCT)** – [Carmen Lefauchery](#), Alexandre Loupy, Sunil Daga, Luis Guirado, Caroline Dudreuilh, Florian Grahammer, Annemarie Weissenbacher
- TH-PO1115 Multi-Center International Study to Validate a Pre-Transplant Blood-Based Next-Generation Sequencing (NGS) Signature Predicting Risk of Acute Rejection After Kidney Transplant** – [Lorenzo G. Gallon](#), Anthony Chang, Michael J. Donovan
- TH-PO1116 Exploring the Pharmacokinetics, Pharmacodynamics, and Safety of Apixaban in Hemodiafiltration: Insights from the HEMOCIONA Study** – [Miguel Hueso](#), Aurema Otero, Elena Rosselló-Palmer, Juan Peris Vidal, Sergi Codina Sanchez, Yurema Martínez Vilar, Raúl Rigo-Bonnin, Nuria Lloberas, Sebastián Videla Cés, HEMOCIONA
- TH-PO1117 SGLT2 Inhibition in Alport Syndrome: First Large-Scale Trial to Plan a Randomized Controlled Trial in Children** – [Oliver Gross](#), Jan Boeckhaus, For the GuARd Alport investigators, International Alport Alliance
- TH-PO1118 NAVKIDS² Trial: A Multi-Centre, Waitlisted, Mixed Methods, Randomized Controlled Trial of a Patient Navigator Intervention in Children with CKD** – [Germaine Wong](#), NAVKIDS² Trial Steering Committee
- TH-PO1119 The TRANSNephro Study Examining a New Transition Model for Post-Kidney Transplant Adolescents: A Multicenter, Randomized Controlled Trial** – [Lars Pape](#), Anika Großhennig, Jenny Pruefe, Martin Kreuzer, Study Group of the German Society of Pediatric Nephrology
- TH-PO1120 Limited Antiproteinuric Efficacy of Dapagliflozin (DPG) in Adolescents with Proteinuric CKD** – [Swathi Ramakrishna](#), Aditi Sinha, Arvind Bagga
- TH-PO1121 Identification of a Hypertensive Endotype with a Median Treatment Effect of -32mmHg in Response to the Novel Aldosterone Synthase Inhibitor Lorundrostat** – [Borut Cizman](#), Luke J. Laffin, Natasa Rajcic, David M. Rodman
- TH-PO1122 Wearable Device for Noninvasive Blood Pressure Monitoring of ICU Patients** – [Forrest Miller](#)
- TH-PO1123 Long-Term Renal Benefit with Nefecon in Chinese Patients with Primary Immunoglobulin A Nephropathy: Two-Year NeflgArd Trial Results** – [Hong Zhang](#), Jens Kristensen, Andrew M. Stone, Bei Wang, Lisa H. Ying, Zhengying Zhu



- TH-PO1124 Sibeprenlimab in Patients with IgA Nephropathy: A Phase 2 Trial** – [Jonathan Barratt](#), Mohit Mathur, Bobby Chacko, Tak Mao D. Chan, Laura Kooienga, Kook-Hwan Oh, Manisha Sahay, Yusuke Suzuki, Muh Geot Wong, Jill Yarbrough, Jing Xia, Brian J. Pereira
- TH-PO1125 Poretacept, an Enhanced Dual BAFF/APRIL Antagonist, in Autoantibody-Associated Glomerulonephritis (GN)** – [James A. Tumlin](#), Harmeet Singh, Frank B. Cortazar, Arvind Madan, Jonathan Barratt, Brad H. Rovin, Hong Zhang, Rupert H. Davies, Amanda M. Enstrom, Allison G. Chunyk, Heather Thomas, Jiahua Li, Sreedhar A. Mandayam
- TH-PO1126 Clinical Value of Adding Dapagliflozin in Patients with Nephrotic Syndrome** – [Magdy ElSharkawy](#), Nahla M. Teama, Mohamed M. Ahmed, Ahmed Emara
- TH-PO1127 Efficacy and Safety of Ravulizumab in a Phase 2 Randomized Controlled Trial in IgA Nephropathy** – [Jonathan Barratt](#), Jose Luis Rocha Castilla, Dario Roccatello, Katherine Garlo, Kara Rice, Richard A. Lafayette
- TH-PO1128 Long-Term Nedosiran Safety and Efficacy in Primary Hyperoxaluria Type 1 (PH1): Interim Analysis of PHYOX3** – [Jaap Groothoff](#), Anne-Laure A. Sellier-Leclerc, Lisa Deesker, Justine Bacchetta, Gesa Schalk, Burkhard Toenshoff, Graham W. Lipkin, Sandrine Lemoine, Horacio Plotkin, Thomas Bowman, Jing Zhou, Bernd Hoppe
- TH-PO1129 The Kidney Transplant Fast Track (KTFT) Intervention Reduced Time to Kidney Transplant Waitlisting** – [Larissa Myaskovsky](#), Arjun L. Kalaria, Chethan M. Puttarajappa, Yue-Harn Ng, Yuridia Leyva, Yiliang Zhu, Miriam E. Velez-Bermudez, Cindy L. Bryce, Chung-Chou H. Chang, L. Ebony Boulware, Amit D. Tevar, Mary Amanda Dew
- TH-PO1130 Twice Weekly vs. Thrice Weekly Hemodialysis in Patients with Residual Kidney Function** – [Seolhyun Lee](#), Nhat M. Pham, Christian G. Bolanos, Saniya S. Bonde, Timothy W. Meyer, Tammy L. Sirich
- TH-PO1131 Hemodialysis Vascular Access Complications: Insights from the ASCEND-D Trial** – [Renato D. Lopes](#), Aleix Cases, Brian Claggett, Laura M. Dember, Nisha Bhatt, Angela R. Jones-Leone, Amy M. Meadowcroft, Mary O. Muoneke, Prerna Ranganathan, Lin Taft, Ajay K. Singh
- TH-PO1132 SARS-CoV-2 Testing During Routine Hemodialysis Care: A Nationwide Pragmatic Clinical Trial** – [Maria E. Montez-Rath](#), Meri Varkila, Xue Yu, Julie Parsonnet, Glenn Chertow, Geoffrey A. Block, Shuchi Anand
- TH-PO1133 Real-World Effectiveness of Hemodialysis Modalities** – [Yan Zhang](#), Anke Winter, Paola Carioni, Belen Alejos, Len A. Usvyat, Franklin W. Maddux
- TH-PO1134 Patient-Reported Health Status of Adults with Kidney Failure Receiving Hemodiafiltration vs. Hemodialysis: Results from the CONVINCe Randomized Controlled Clinical Trial** – [Matthias Rose](#), Felix Fischer, Gregor Liegl, Giovanni Strippoli, Carinna Hockham, Robin W. Vernooij, Claudia M. Barth, Bernard J. Canaud, Adrian Covic, Krister Cromm, Andrew Davenport, Kathrin I. Fischer, Jorgen B. Hegbrant, Hanna Jaha, Anna Schappert, Marietta Török, Michiel L. Bots, Peter J. Blankestijn, For the CONVINCe Scientific Committee and Investigators
- TH-PO1135 Short- and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis (SLEEP-HD)** – [Rajnish Mehrotra](#), Daniel Cukor, Susan M. McCurry, Tessa Rue, Maria-Eleni Roumelioti, Patrick J. Heagerty, Mark L. Unruh
- TH-PO1136 WITHDRAWN**



- TH-PO1137 Peer Mentorship to Reduce Hospitalizations Among Patients Receiving Maintenance Hemodialysis: Results of the PEER-HD Trial** – [Ladan Golestaneh](#), Michal L. Melamed, Ryung S. Kim, Kerri L. Cavanaugh
- TH-PO1138 Association of CKD-Associated Pruritus (CKDaP) with More Sleep Disorders, Increased Pain, and Worse Fatigue in US Hemodialysis Patients** – [Tejas Desai](#), Rachel A. Lasky, Kunal Malhotra, Hans-Juergen Arens, Juliana H. Oliveira, Michael S. Anger
- TH-PO1139 The Association Between Pruritus Severity and Mental Health-Related Quality of Life in over 80,000 Hemodialysis Patients** – [Linda Ficociello](#), Tejas Desai, Juliana H. Oliveira, Hans-Juergen Arens, Rachel A. Lasky, Michael S. Anger
- TH-PO1140 Strategies for the Management of Atrial Fibrillation in PatiEnts Receiving Dialysis (SAFE-D)** – [Ziv Harel](#), SAFE-D Investigators
- TH-PO1141 The FAGOTTO Trial: Randomized Controlled Trial for Impact on Renal Hemodynamics of the SGLT2 Inhibitor Canagliflozin in Diabetic Kidney Disease** – [Nobuhiro Nishibori](#), Sawako Kato, Yosuke Saka, Toshihiro Mizukoshi, Tomohiko Naruse, Hirotake Kasuga, Takashi Miyata, Masahiko Ando, Yachiyo Kuwatsuka, Hiroshi Arima, Shoichi Maruyama
- TH-PO1142 Impact of Finerenone-Induced Albuminuria Reduction on CKD Outcomes in Type 2 Diabetes: A Causal Mediation Analysis** – [Rajiv Agarwal](#), Wanzhu Tu, Alfredo E. Farjat, Youssef M. Farag, Robert D. Toto, Sanjay Kaul, Robert Lawatscheck, Katja Rohwedder, Luis M. Ruilope, Peter Rossing, Bertram Pitt, Gerasimos Filippatos, Stefan D. Anker, George L. Bakris, FIDELIO-DKD and FIGARO-DKD Investigators
- TH-PO1143 Results of an Exploratory and Randomized Control Study on DAPagliflozin for the Attenuation of Albuminuria in Patients with HEaRt Failure and Type 2 Diabetes Mellitus: DAPPER Study** – [Fumiki Yoshihara](#), Miki Imazu, Ichiro Sakuma, Yukio Hiroi, Hisao Hara, Osamu Okazaki, Chizuru Ishiguro, Chisato Izumi, Teruo Noguchi, Toshihiko Shiraiwa, Norio Nishioka, Kenshi Fujii, Katsuomi Iwakura, Osamu Tomonaga, Koichi Kobayashi, Masahiro Takihata, Kazuhiko Yumoto, Hiroyuki Takase, Toshiharu Himi, Masanori Asakura, Takanori Kawabata, Katsuhiko Omae, Shin Ito, Masafumi Kitakaze, DAPPER Investigators
- TH-PO1144 Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD** – [Vikas Sridhar](#), Ayodele Odutayo, Satish K. Garg, Thomas Danne, Alessandro Doria, Michael Mauer, Michael J. Davies, Phillip Banks, Manon Girard, David Cherney
- TH-PO1145 The ALL STAR CKD Trial: Pleiotropic Effect of Atorvastatin Focused on Renoprotection in Patients with CKD** – [Eriko Yamamoto](#), Sawako Kato, Masahiko Ando, Shoichi Maruyama, Yoshinari Yasuda
- TH-PO1146 A Clinical Decision Support Intervention Results in a Clinically Significant Decrease in Mean Systolic Blood Pressure in a Pragmatic Clinical Trial in a Primary Care Setting** – [Lipika Sama](#), John L. Kilgallon, Stuart R. Lipsitz, Heather J. Baer, Michael P. Gannon, Ryan Dunk, Weng Ian Chay, Richard J. Fay, Pamela Garabedian, Edward Wu, Joseph V. Bonventre, Gearoid M. McMahon, Sushrut S. Waikar, Patricia Dykes
- TH-PO1147 A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Enarodustat for the Treatment of Renal Anemia in Chinese Non-Dialysis CKD Patients** – [Xueqing Yu](#), Zhiming Ye, Xinling Liang, Yanning Zhang, Weiping Hu, Xiaonong Chen, Tianjun Guan, Hua Zhou, Ping Fu, Yunhua Liao, Hui Xu, Aicheng Yang, Hongwen Zhao, Lili Yang, Yujie Sun, Yongzhen Xiao
- TH-PO1148 WITHDRAWN**



- TH-PO1149 **Real-World Effectiveness of SGLT2 Inhibitors on the Progression of Kidney Disease in Non-Diabetic CKD Patients with and Without Albuminuria** – [Afif Nakhleh](#), Sivan Gazit, Adi Gross, Adva Yarden, Naim Shehadeh, Muhammad Abdul-Ghani, Cheli Melzer Cohen
- TH-PO1150 **Effect of Curcumin on Vascular and Cognitive Function in CKD: A Randomized Controlled Trial** – [Colin J. Gimblet](#), Nicholas T. Kruse, Katharine M. Geasland, Jeni Michelson, Mingyao Sun, Patrick Ten Eyck, Meenakshi Sambharia, Matthew Rossmo, Carinda Linkenmeyer, Manjula Tamura, Michel Chonchol, Douglas R. Seals, Karin Hoth, Diana I. Jalal
- TH-PO1151 **Electronic Health Record-Based Population Health Management to Optimize Care in CKD: Kidney CHAMP Randomized Clinical Trial** – [Manisha Jhamb](#), Melanie R. Weltman, Susan M. Devaraj, Linda-Marie U. Lavenburg, Zhuoheng Han, Alaa A. Alghwiri, Gary Fischer, Bruce L. Rollman, Thomas D. Nolin, Jonathan Yabes
- TH-PO1152 **Control of Secondary Hyperparathyroidism with Extended-Release Calcifediol Is Associated with Slower CKD Progression** – [Charles W. Bishop](#), Stephen A. Strugnelli, Akhtar Ashfaq
- TH-PO1153 **Heart Failure and Edema Events Associated with Sodium Zirconium Cyclosilicate vs. Patiromer Treatment** – [Nihar Desai](#), Abisola Olopoenia, Jennifer A. Kammerer, Jeffrey J. Budden, Alexandra C. Gordon, Asa C. Tysseling
- TH-PO1154 **Real-World Effectiveness of Finerenone in Chinese CKD Patients Without Type 2 Diabetes** – [Li Zhou](#), Wenge Li
- TH-PO1155 **Hexasodium Fytate (SNF472) for Treatment of Calciphylaxis** – [Smeeta Sinha](#), Sagar U. Nigweka, Lisa Gould, Thomas E. Serena, Sharon M. Moe, George R. Aronoff, Dinesh K. Chatoth, Jeffrey L. Hymes, Kevin Carroll, Gabriela Alperovich Lehrer, Laurence H. Keller, Joan Perelló, Alex Gold, Glenn Chertow
- TH-PO1156 **Targeting Vascular Calcification in Calciphylaxis** – [Sagar U. Nigwekar](#), On behalf of VitK-CUA trial investigators
- TH-PO1157 **A Randomized, Controlled, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Lower Starting Dose Roxadustat for Anemia Treatment in Patients with CKD Not on Dialysis** – [Ping Li](#), Guangyan Cai, Xuefeng Sun, Yiqing Wu, Cuihua Huang, Shuting Pan, Xiangmei Chen
- TH-PO1158 **CER-001, an Engineered High-Density Lipoprotein, Shows Beneficial Pleiotropic Effects in Patients with Sepsis in RACERS: A Phase 2A Randomized Control Trial** – [Marco Fiorentino](#), Alessandra Stasi, Rossana Franzin, Loreto Gesualdo
- TH-PO1159 **WITHDRAWN**
- TH-PO1160 **Results of a Randomized Placebo-Controlled Double-Blind Adaptive Phase 2 Study (AKITA) Evaluating RMC-035 for the Prevention of AKI in Patients Undergoing Cardiac Surgery** – [Alexander Zarbock](#), Jay L. Koyner, Andreas Boening, Daniel Engelman, Claudio Ronco, Michael Reusch, Tobias Agervald